Yungjin Pharm Co Ltd

Yungjin Pharm Co Ltd has a market price of 1,510 KRW per share, with a market capitalization of 276,167,605,540 KRW, indicating a relatively high valuation compared to its tangible book value of 3.02. The company's price-to-book ratio is 3.02, and its enterprise value to revenue ratio is 1.46, suggesting a moderate valuation relative to its revenue. However, the company's enterprise value to EBITDA ratio is 100.16, which is significantly high and may indicate overvaluation or poor profitability. The company's profitability is weak, with a return on equity of -0.25% and a return on assets of -0.09%, both of which are below the industry median for pharmaceutical companies. The net income for the period is negative at -227,660,610 KRW, indicating a loss, which is a concern for investors. The gross profit margin is 30.35%, and the operating margin is 1.45%, both of which are below the industry average, suggesting inefficiencies in cost management or pricing power. Yungjin Pharm Co Ltd's revenue is primarily concentrated in South Korea, with no significant international exposure disclosed in the available data. The company's revenue concentration in a single geographic region increases its vulnerability to local economic and regulatory changes. The company's operating cash flow is positive at 11,730,228,390 KRW, but its free cash flow is negative at -3,425,190,270 KRW, indicating that capital expenditures are outpacing operating cash flow. The company's growth trajectory is mixed. While the current fiscal year is expected to show a slight improvement in revenue, the next fiscal year is projected to see a decline. The capital expenditure for the period is -11,963,760,660 KRW, indicating a significant investment in long-term assets, which could support future growth but is currently reducing free cash flow. The company's debt-to-equity ratio is 1.03, and its current ratio is 1.48, suggesting moderate liquidity risk. The company faces several risk factors, including a negative net cash position after subtracting total debt, which is a red flag for liquidity. The risk assessment indicates a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. The company's recent financial performance, including a net loss, may also impact its creditworthiness and investor confidence. Recent events, such as the company's financial filings and transcripts, have not indicated any major strategic shifts or new product launches that could significantly alter its trajectory. The company's focus remains on its core pharmaceutical business, with no significant diversification into new markets or product lines.